Dragon Announces Appointment of General Manager of Chinese Operations

Dragon Announces Appointment of General Manager of Chinese
Operations 


VANCOUVER, May 4  /PRNewswire-FirstCall/ -- Dragon Pharmaceutical Inc. (OTC BB:
DRUG; TSX: DDD) today announced the appointment of Mr. Xiaochun Zhang as the
General Manager of the Company's Chinese operations.

As the General Manager of our Chinese operations, Mr. Zhang is responsible for
the overall operational and sales and marketing management of the Pharma and
Chemical divisions. Such responsibilities will be extended to cover the Biotech
division after its relocation from its current location in Nanjing city.

Mr. Zhang has 20 years of expertise in large-scale fermentation processes as a
chemical engineer together with operational experience with various Chinese and
international pharmaceutical companies. Prior to joining Dragon, Mr. Zhang was
the Deputy General Manager of Aurobindo Bio-pharma Co. Ltd. in Datong, China, a
subsidiary of one of the largest pharmaceutical companies in India. Mr. Zhang
started his career as an engineer in the fermentation workshop in Zhangjiakou
Pharmaceutical Co. Ltd., and became the Deputy General Manager of the company
in 1997. In the same year, Mr. Zhang was appointed as the General Manager of
GIST-Brocades Pharmaceutical Ltd., a joint venture in China between Zhangjiakou
Pharmaceutical Co. Ltd. and Netherlands' DSM, one of the largest chemical
companies in the world.

Mr. Zhang holds a Bachelor degree in chemical mechanical engineering from Hebei
University of Technology and is currently participating in an Executive MBA
program from the Helsinki School of Economics and Business Administration. Mr.
Zhang is based in our office in Datong city, China.

About Dragon Pharmaceutical Inc.

On January 12, 2005, Dragon completed the acquisition of Oriental Wave Holding
Limited. As a result of the acquisition, Dragon has transformed itself into a
diversified and growth oriented generic pharmaceutical company with three key
business units: (1) Pharma division for 44 generic prescription,
over-the-counter and sterilized bulk drugs; (2) Chemical division for bulk
pharmaceutical chemicals and intermediates (Clavulanic Acid and 7-ACA,
Abamectin); and (3) Biotech division for recombinant drugs (EPO and G-CSF). The
Company, after the acquisition, has significantly increased the size of
operations and now has four manufacturing facilities in China (three in Datong
city and one in Nanjing city), approximately 1,800 employees, with over 1,200
sales representatives in China, and approximately 55 key products in 86
different dosages and presentations currently in the market.

  For further information please contact:
  Dragon Pharmaceutical Inc.
  Garry Wong, CFA, IMBA
  Telephone: [phone] or North America Toll Free: 1-877-388-3784
  Email: 
  Website: http://www.dragonpharma.com/

  or

  Renmark Financial Communications Inc.
  John Boidman : 
  Sylvain Laberge : 
  Media - Cynthia Lane : 
  Telephone: [phone]
  Website: http://www.renmarkfinancial.com/



This press release contains forward looking statements. These statements are
subject to certain risks and uncertainties that could cause actual results to
differ materially from those anticipated in the forward looking statement.
Readers should not place undue reliance on forward looking statements, which
only reflect the view of management as of the date hereof. The Company does not
undertake the obligation to publicly revise these forward looking statements to
reflect subsequent events or circumstances. Readers should carefully review the
risk factors and other factors described in its periodic reports with the
Securities and Exchange Commission. 

DATASOURCE: Dragon Pharmaceuticals Inc.



CONTACT: Dragon Pharmaceutical Inc.: Garry Wong, CFA, IMBA, Telephone:

[phone], North America Toll Free: 1-877-388-3784, Email:

, Website: http://www.dragonpharma.com/; Renmark

Financial Communications Inc.: John Boidman, ;

Sylvain Laberge, ; Media: Cynthia Lane,

, Telephone: [phone], Website:

http://www.renmarkfinancial.com/

Copyright